Abstract library

98 results for "Lewczuk-Myślińska".
#1114 CT Evaluation of Gastric Neuroendocrine Neoplasm Based on WHO 2010 Classification
Introduction: The 2010 WHO classification classifies GEP-NEN into grade 1, 2 and 3.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Li Z W, Tang L, Cao K, ...
#1290 PD-L1 Expression is Associated with Grade of Neuroendocrine Tumors
Introduction: Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs).The correlation between Gastroenteropancreatic Neuroendocrine Neoplasms (GEPNENs) and immunocheck point molecule-PD-L1 is still unclear now.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Professor Zhongwu Li
Authors: Li Z, Leng J, Wang H, Li S, ...
#1378 Evaluation of CT Prognostic Factors of Neuroendocrine Liver Metastasis Treated with Transcatheter Arterial Embolization
Introduction: TAE has been shown to be effective in the management of metastatic NET.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Liu P, Cao K, Li J, ...
#1429 Evaluate the Accuracy of Pathological Diagnosis on Biopsy Specimens from Gastrointestinal Neuroendocrine Tumors
Introduction: Gastrointestinal neuroendocrine neoplasms (GI-NENs) is a highly heterogeneous tumor. The accuracy of pathological diagnosis on the biopsy is crucial for GI-NENs but rarely investigated
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Doctor Li Sun
Authors: Sun L, Li S, Li J, Lu M, ...
#1473 Long-term Outcomes of Colorectal Neuroendocrine Tumors: A Sub Group Analysis of 29 G3 Cases According to the 2010 WHO Classification
Introduction: Colorectal neuroendocrine tumors (NETs) are a group of heterogenous neoplasm.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Jiahua Leng
Authors: Leng J, Li Z W, Li Y, Chen Z S, ...
#1660 The Clinicopathological Characteristics of Small Intestinal Neuroendocrine Neoplasms: A Multicenter Retrospective Study from China
Introduction: Small intestinal NEN (SI-NEN) is much rarer in Asian countries. Hence, the clinicopathological characteristics of SI-NEN are still unknown in Asian population.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Jie Chen
Authors: Chen L, Zhou L, Zhang M, Shang L, ...
#1697 An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Authors: Xu J, Li J, Bai C M, Xu N, ...
Keywords: sulfatinib, net, orr, pfs
#2125 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
Introduction: Definitions of Type 3 gastric NEN (g-NEN) in ENETS Guidelines 2012 and 2016 are ambiguous and controversial, so Four-type classification has been proposed in China.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Zhang P, Qiu X D, Li X K, ...
#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Jie Li
Authors: Li J, Xu J, Zhou Z, Bai C, ...
#677 Care of NET Patients at the Skåne University Hospital-Lund University, Sweden: A Model for the Multidisciplinary Approach to the Diagnosis and Treatment of NET
Introduction: The varied and nonspecific symptoms of neuroendocrine tumors (NET) often delay diagnosis until the disease has progressed. Input from various medical specialties can improve access to and delivery of care.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Erik Nordenström